As our knowledge and understanding of the microbiome has grown, so has the recognition that these microscopic hitchhikers play a critical role in human health as well as in disease. The relationship between the gut microbiota and conditions like nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) is an active area of research, with data hinting that the abundance of certain bacterial species, or an imbalance in the relative levels of different species, is linked to the incidence of these ailments. In regard to CVD, the hypothesis is that certain microbes regulate the level of plasma lipopolysaccharides, which in turn dials the immune response up or down, impacting atherosclerotic lesion formation. In NAFLD, multiple hits—for example overnutrition and gut microbiome dysbiosis—may influence the transition from NAFLD to inflammation-based liver disease. Additionally, the associations between bacterial genera and disease appear to vary across ethnicity/race.
This webinar will investigate how the makeup of the gut microbiome impacts NAFLD and CVD in particular, and human health in general, and how better understanding this impact might lead to the development of more effective therapies.
During the webinar, the speaker will:
- Outline how changes in the abundance of certain bacterial species might create conditions that promote the occurrence of certain diseases
- Explain specific pathways through which molecules secreted by the gut microbiome might impact disease
- Describe how this data might inform the development of new and different therapies or modes of treatment
- Answer audience questions during the live broadcast.
This webinar will last for approximately 60 minutes.